Clinical and acoustic measures of the negative syndrome
- PMID: 7491386
Clinical and acoustic measures of the negative syndrome
Abstract
We studied 12 male schizophrenia patients in a 6-week treatment trial comparing two neuroleptics and placebo. Efficacy in regard to negative symptoms was of interest, and Alphs' Negative Symptom Assessment (NSA) was included. The NSA includes behaviorally anchored ratings such as "prolonged time to response" and "restricted speech output." Audio recordings of interviews with the patients were analyzed acoustically. In general, the behavioral anchors did not prevent the ratings from being influenced by global impressions. There was a strong correlation between each item and the total of other items, but a modest correlation with the relevant behavioral measure. Results suggest that, even with specific and behaviorally anchored items, the clinician's assessment is confounded by global impressions. Treatment effects were greater for the acoustic measures than for the clinical measures.
Similar articles
-
Ziprasidone and amisulpride effectively treat negative symptoms of schizophrenia: results of a 12-week, double-blind study.Int Clin Psychopharmacol. 2006 May;21(3):143-51. doi: 10.1097/01.yic.0000182121.59296.70. Int Clin Psychopharmacol. 2006. PMID: 16528136 Clinical Trial.
-
Mirtazapine add-on therapy in the treatment of schizophrenia with atypical antipsychotics: a double-blind, randomised, placebo-controlled clinical trial.Hum Psychopharmacol. 2009 Apr;24(3):233-8. doi: 10.1002/hup.1017. Hum Psychopharmacol. 2009. PMID: 19330802 Clinical Trial.
-
Beneficial antipsychotic effects of allopurinol as add-on therapy for schizophrenia: a double blind, randomized and placebo controlled trial.Prog Neuropsychopharmacol Biol Psychiatry. 2005 Feb;29(2):253-9. doi: 10.1016/j.pnpbp.2004.11.008. Epub 2004 Dec 28. Prog Neuropsychopharmacol Biol Psychiatry. 2005. PMID: 15694232 Clinical Trial.
-
Zotepine versus placebo in the treatment of schizophrenic patients with stable primary negative symptoms: a randomized double-blind multicenter trial.Pharmacopsychiatry. 2004 Nov;37(6):270-8. doi: 10.1055/s-2004-832683. Pharmacopsychiatry. 2004. PMID: 15551193 Clinical Trial.
-
Lurasidone in the treatment of acute schizophrenia: a double-blind, placebo-controlled trial.J Clin Psychiatry. 2009 Jun;70(6):829-36. doi: 10.4088/JCP.08m04905. Epub 2009 Jun 2. J Clin Psychiatry. 2009. PMID: 19497249 Clinical Trial.
Cited by
-
Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders.Cochrane Database Syst Rev. 2015 Jan 16;1(1):CD009831. doi: 10.1002/14651858.CD009831.pub2. Cochrane Database Syst Rev. 2015. PMID: 25592299 Free PMC article.
-
Haloperidol versus placebo for schizophrenia.Cochrane Database Syst Rev. 2013 Nov 15;2013(11):CD003082. doi: 10.1002/14651858.CD003082.pub3. Cochrane Database Syst Rev. 2013. PMID: 24242360 Free PMC article.
-
Avolition and expressive deficits capture negative symptom phenomenology: implications for DSM-5 and schizophrenia research.Clin Psychol Rev. 2011 Feb;31(1):161-8. doi: 10.1016/j.cpr.2010.09.002. Epub 2010 Sep 18. Clin Psychol Rev. 2011. PMID: 20889248 Free PMC article. Review.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Medical